Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.82 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828773 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL16981492 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL997576 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL851151 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL828774 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL10303810 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL18768649 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL828775 | 1.00 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL11930623 | 0.95 | CTSS (0.84) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL996413 | 0.94 | CTSS (0.74) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| EP-2937339-A1 | Macrocylic inhibitors of hepatitis c virus | Janssen Sciences Ireland UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2010072742-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-2121674-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | TIBOTEC PHARM LTD (IE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-18 | — | — | US | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2008092954-A2 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20100041889-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | PREP, SPINT2, PEPD | CTSS 31/4885CTSB 27/4885ADRB3 4662/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | HLA-DRB1, CYP3A43, HAVCR2 | CTSS 723/4885CTSB 438/4885ADRB3 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.